A Prospective, Multicenter, Phase -IV Study to Assess the Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) Patients
A Prospective, Multicenter, Phase -IV Study to Assess the Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) Patients is a PHASE4 clinical asset sponsored by AstraZeneca in Type 2 Diabetes Mellitus. SEO and diligence focus: dapagliflozin and saxagliptin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Type 2 Diabetes Mellitus
Modality: combination therapy
Target: dapagliflozin and saxagliptin
Sponsor: AstraZeneca
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 22, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: dapagliflozin and saxagliptin
View original source fields
Condition raw: Type 2 Diabetes Mellitus
Condition normalized: Type 2 Diabetes Mellitus
Modality raw: combination therapy
Modality normalized: combination therapy
Target raw: dapagliflozin and saxagliptin
Target normalized: dapagliflozin and saxagliptin